| 產品描述： | GSK2606414 is a cell-permeable and orally available protein kinase R-like endoplasmic reticulum (ER) kinase (PERK) inhibitor with an IC50 of 0.4 nM. |
| 靶點： |
EIF2AK3 (PERK):0.4 nM (IC50);EIF2AK1 (HRI):420 nM (IC50);EIF2AK2 (PKR):696 nM (IC50);Apoptosis;PERK;Autophagy |
| 體內研究： |
GSK2606414 (50 and 150 mg/kg, p.o.) inhibits the growth of a human tumor xenograft in mice |
| 參考文獻： |
1. Axten JM, et al. Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulu 2. Zhang M, et al. Inhibiting the Plasmodium eIF2α Kinase PK4 Prevents Artemisinin-Induced Latency. Cell Host Microbe. 2017 Dec 13;22(6):766-776.e4. |
| 溶解性： |
DMSO : ≥ 100 mg/mL (221.51 mM) |
| 保存條件： |
-20℃ |
| 配置溶液濃度參考： |
|
1mg |
5mg |
10mg |
| 1 mM |
2.215 ml |
11.076 ml |
22.151 ml |
| 5 mM |
0.443 ml |
2.215 ml |
4.43 ml |
| 10 mM |
0.222 ml |
1.108 ml |
2.215 ml |
| 50 mM |
0.044 ml |
0.222 ml |
0.443 ml |
|
| 注意： |
部分產品我司僅能提供部分信息，我司不保證所提供信息的權威性，僅供客戶參考交流研究之用。 |
上海工商
危險品化學品經營許可證（不帶存儲）
營業執照(三證合一)
北京